Clinical trial · Interventional
Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas (TACE-KMG)
Clinical Trial of Transcatheter Arterial Chemoembolization (TACE)With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas
NCT01393197CI-TRIAL-00020238TACE-KMGunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the effects of Transcatheter Arterial Chemoembolization (TACE) with KMG microsphere in treating HCC. And to determine which one is better,KMG microsphere or lipiodol?
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Hepatocellular | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Therapeutic Chemoembolization | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- ACTIVE_COMPARATOR
- label
- TACE -oil
- description
- embolization agent:Iodinated Oil or /and gelatin sponge Iodinated Oil （5-30ml）with Epirubicin （30-40mg/m2） or and gelatin sponge
- interventionNames
- Other: Therapeutic Chemoembolization
- type
- EXPERIMENTAL
- label
- TACE-KMG ( routine dose Chemo)
- description
- embolization agent:KMG microsphere( 150-450µm,0.2-2g) with routine dose Epirubicin （30-40mg/m2）
- interventionNames
- Other: Therapeutic Chemoembolization
- type
- EXPERIMENTAL
- label
- TACE-KMG( low dose Chemo )
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Hepatocellular Carinomas with diagnosis of pathology or cytology or consistent with China 2001 guideline of Clinical Diagnosis Hepatocellular Carinomas clinical stage（The Barcelona Liver Clinic staging system,BCLC B and C)，or can not receive surgical intervention * liver function:Child-Pugh A、B * PST 0-1（Eastern Cooperative Oncology Group Performance Score ,ECOG） * Lifespan≥6 months * First time to receive treatment * Can accept the follow up * informed consent was gotten * the number of lesion ≤ 5 Exclusion Criteria: * pregnant or lactation woman * emotional disturbance * serious heart ,lung disfunction or serious diabetes mellitus * serious reactiveness infections;（exp:type B or C hepatitis） * liver function :Child-Pugh Score C * thrombocyte\<6×109/L * diffuse HCC * widespread metastasis * serious atherosclerosis * acquired immunodeficiency syndrome;AIDS * thrombosis or thrombosis event in 6 months * renal inadequacy who need hemodialysis or peritoneal dialysis * with other tumors except basal cell carcinoma and carcinoma in situ of cervix * serious alimentary tract hemorrhage in 4 weeks
References
Publications (0)
Data not yet available
No reference posted for this study.